Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates...

Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom;
Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification
and Distortion; Company Questions What Else Karkus May Be Hiding From
Shareholders

DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation,
(Nasdaq: QGLY), www.quigleyco.com, today announced that it has uncovered
additional facts with respect to the relationship between Ted Karkus and Dr.
Richard Rosenbloom. The following are among the facts that were uncovered:

1. Karkus admitted in a press release today that he loaned $55,000 to Dr.
Rosenbloom. Karkus is, and has been, a shareholder of The Quigley
Corporation and Dr. Rosenbloom is, and has been, in possession of
material non-public information as to the Company's drug candidate
development programs during the term of the loan.
2. In sworn testimony, Karkus stated that at no time did he have any
financial arrangement with any employee of The Quigley Corporation. By
his own admission in today's press release, this is a false
statement which he made under oath.
3. Karkus has been in touch with Company officials. The fact has never
been
disclosed in the proxy materials or otherwise.
4. In clear violation of Company policy, Dr. Rosenbloom has never
disclosed
his relationship with dissident Karkus.
5. According to Dr. Rosenbloom in an interview conducted by executives of
the Company prior to The Quigley Corporation's press release earlier
today, Dr. Rosenbloom advised that he had been offered an increase in
salary and an undisclosed amount of stock to continue with the Karkus
Group if the Karkus Group were victorious in gaining control of the
Company.

6. The proposed arrangement between Karkus and Dr. Rosenbloom has never
been
disclosed in any of Karkus's proxy solicitation material in
violation of federal securities laws.

The Company assures its shareholders that there will be minimal impact, if
any, on the Company's Pharma division with the suspension of Dr. Rosenbloom.
Dr. Rosenbloom's role in the ongoing development programs has been shifting to
Michael Petterutti for the past several months and during the time of this
unfortunate breach of Company policy.

We urge Shareholders to take this information into consideration and vote the
White Proxy Card.

About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a
diversified natural health medical science company. Its Cold Remedy segment
is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges,
gums and sugar free tablets clinically proven to cut the common cold nearly in
half. COLD-EEZE customers include leading national wholesalers and
distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies. The Quigley Corporation has several wholly owned
subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved
facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other
contract manufacturing opportunities. Quigley Pharma Inc.
(http://www.QuigleyPharma.com) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived potential
prescription drugs.

Forward-Looking Statements
Certain statements in this press release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and
involve known and unknown risk, uncertainties and other factors that may cause
the Company's actual performance or achievements to be materially different
from the results, performance or achievements expressed or implied by the
forward-looking statement. Factors that impact such forward-looking statements
include, among others, changes in worldwide general economic conditions,
changes in interest rates, government regulations, and worldwide competition.

Important Additional Information
The Quigley Corporation ("Quigley" or the "Company") filed a definitive proxy
statement with the Securities and Exchange Commission (the "SEC") on April 2,
2009 in connection with the 2009 Annual Meeting of Stockholders and began the
process of mailing the definitive proxy statement and a WHITE proxy card to
stockholders. The Company's stockholders are strongly advised to read
Quigley's proxy statement as it contains important information. Stockholders
may obtain an additional copy of Quigley's definitive proxy statement and any
other documents filed by the Company with the SEC for free at the SEC's
website at http://www.sec.gov. Copies of the definitive proxy statement are
available for free at
http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=07814.
In addition, copies of the Company's proxy materials may be requested at no
charge by contacting MacKenzie Partners, Inc. at 1-800-322-2885 or via email
at quigley@mackenziepartners.com. Detailed information regarding the names,
affiliations and interests of individuals who are participants in the
solicitation of proxies of Quigley's stockholders is available in Quigley's
definitive proxy statement filed with SEC on April 2, 2009.

CONTACT:

Gerard M. Gleeson Mark Harnett / Bob Marese
The Quigley Corporation MacKenzie Partners, Inc.
Vice President, CFO (212) 929-5500
(215) 345-0919 Quigley@mackenziepartners.com

Investor Relations
Carl Hymans
G. S. Schwartz & Co.
212-725-4500
carlh@schwartz.com

SOURCE Quigley Corporation

Gerard M. Gleeson, Vice President, CFO of The Quigley Corporation,
+1-215-345-0919; or Mark Harnett or Bob Marese, both of MacKenzie Partners,
Inc., +1-212-929-5500, Quigley@mackenziepartners.com; or Investor Relations,
Carl Hymans of G. S. Schwartz & Co., +1-212-725-4500, carlh@schwartz.com